22q112 deletion syndrome epidemiology forecast
- According to DelveInsight’s analysis, the total diagnosed prevalent cases of 22q11.2 Deletion Syndrome were approximately 101,500 in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
- 22q11.2 Deletion Syndrome also known as DiGeorge syndrome or velocardiofacial syndrome, is a genetic disorder caused by a microdeletion on chromosome 22q11.2, resulting in multisystem manifestations including congenital heart defects, immune dysfunction, hypocalcemia, and distinct craniofacial features.
- It is a lifelong condition and the most common chromosomal microdeletion syndrome, significantly impacting development, cognition, and behavioral health, with an estimated prevalence of ~1 in 4,000 live births.
- A substantial proportion of patients experience neurocognitive impairment and psychiatric disorders, including a markedly elevated risk of schizophrenia (~25% in adults), making 22q11.2DS one of the strongest known genetic risk factors for severe mental illness.
- The underlying pathophysiology involves gene dosage imbalance (notably TBX1), disrupted embryologic development, immune dysfunction, and altered neurodevelopmental pathways, complicating target identification and therapeutic development.
- Diagnosis is often delayed due to phenotypic heterogeneity and absence of standardized clinical screening pathways, with many cases identified only after multiple specialist referrals, highlighting a persistent diagnostic gap and missed early intervention window.
22q11.2 Deletion Syndrome Epidemiology Forecast in the 7MM
-
2025 Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome: ~101,500
-
22q11.2 Deletion Syndrome Growth Rate (2026–2036): ~14 % CAGR
DelveInsight's ‘22q11.2 Deletion Syndrome Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
|
Study Period
|
2022–2036
|
|
Historical Year
|
2022–2025
|
|
Forecast Period
|
2026–2036
|
|
Base Year
|
2026
|
|
Geographies Covered
|
-
North America: The US;
-
Europe: Germany, France, Italy, Spain, and the UK;
-
Asia-Pacific: Japan
|
|
22q11.2 Deletion Syndrome Epidemiology CAGR (Forecast period)
|
~14% (2026–2036)
|
|
22q11.2 Deletion Syndrome Epidemiology Segmentation Analysis
|
Patient Burden Assessment
-
Total Prevalent Cases of 22q11.2 Deletion Syndrome
-
Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome
-
Age-specific Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome
-
Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome with Behavioral And Psychiatric
-
Total Treated Cases of 22q11.2 Deletion Syndrome
|
22q11.2 Deletion Syndrome Understanding and Diagnosis
22q11.2 Deletion Syndrome Overview and Diagnosis
22q11.2 Deletion Syndrome (22q11.2DS) is a chromosomal microdeletion disorder caused by a hemizygous deletion at the 22q11.2 locus, leading to haploinsufficiency of critical developmental genes, particularly TBX1. It presents with multisystem involvement, most commonly including conotruncal congenital heart defects, thymic hypoplasia with immune dysfunction, hypoparathyroidism-associated hypocalcemia, and craniofacial anomalies, along with significant neurodevelopmental and psychiatric manifestations such as learning disabilities, autism spectrum disorder, and a markedly increased risk of schizophrenia. With a prevalence of approximately 1 in 3,000–4,000 live births, it is the most common chromosomal microdeletion syndrome; however, variable expressivity and age-dependent clinical evolution often lead to underdiagnosis, particularly in individuals without major congenital anomalies.
Further details are provided in the report...
Diagnosis
Diagnosis of 22q11.2DS is genetically confirmed, with chromosomal microarray (CMA) as the current gold standard, enabling detection of both typical (~3 Mb) and smaller nested deletions, while FISH is now less preferred due to limited sensitivity for atypical variants. Clinical suspicion is typically raised in patients presenting with congenital heart disease, hypocalcemia, immune deficiency, or developmental delay, but the absence of standardized screening criteria contributes to frequent diagnostic delays. Increasing adoption of genomic-first approaches and prenatal screening (NIPT) is improving early detection, although milder phenotypes continue to be diagnosed later in childhood or adulthood, reflecting persistent gaps in recognition and testing practices.
Further details are provided in the report....
22q11.2 Deletion Syndrome Epidemiology
Key Findings from 22q11.2 Deletion Syndrome Epidemiological Analysis and Forecast
- According to DelveInsight’s estimates, in 2025, the total number of diagnosed prevalent cases of 22q11.2 deletion syndrome in the 7MM was ~97,200.
- In the United States, among age-specific diagnosed prevalent cases of 22q11.2 deletion syndrome, infant accounted for the majority of cases (~12,550), followed by 1 ̶ 5 years (~10,300), 6 ̶ 12 years (~19,550), 18+ years (~7,000), and 13 ̶ 17 years (~4,800) in 2025.
- Among EU4 and the UK Germany accounted for the highest number of diagnosed prevalent cases of 22q11.2 Deletion Syndrome, while Spain reported the lowest burden in 2025, highlighting regional variability in diagnosis and disease recognition.
- In Japan, the diagnosed prevalent cases of 22q11.2 deletion syndrome with behavioral and psychiatric phenotypes were approximately 7,650 in 2025.
Explore comprehensive insights into the 22q11.2 Deletion Syndrome market landscape, including epidemiology trends, emerging therapies, and future growth opportunities through 2036.
Scope of the Report
- The report covers a segment of key events, an executive summary, a descriptive overview of 22q11.2 Deletion Syndrome, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
- 22q11.2 Deletion Syndrome Patient Population Forecast
Report Key Strengths
- Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
- Artificial Intelligence (AI)-Enabled Market Research Report
- 11-Year Forecast
FAQs
- What are the disease risks, burdens, and unmet needs of 22q11.2 Deletion Syndrome? What will be the growth opportunities across the 7MM concerning the patient population with 22q11.2 Deletion Syndrome?
- What is the historical and forecasted 22q11.2 Deletion Syndrome patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
1. Key Insights
2. Report Introduction
3. Executive Summary of 22q11.2 Deletion Syndrome
4. Epidemiology Forecast Methodology
5. 22q11.2 Deletion Syndrome Patient Overview at a Glance
5.1 Patient Share (%) Distribution by Country in 2025 in the 7MM
5.2 Patient Share (%) Distribution by Country in 2036 in the 7MM
6. Disease Background and Overview
6.1 Introduction
6.2 Cause and Inheritance
6.3 Signs and Symptoms
6.4 Complications
6.5 Pathophysiology
6.6 Diagnosis
6.6.1 Differential Diagnosis
6.6.2 Diagnosis Algorithm
6.6.3 Diagnosis Guidelines
7. Epidemiology and Patient Population
7.1 Key Findings
7.2 Assumptions and Rationale
7.3 Total Prevalent Cases of 22q11.2 Deletion Syndrome in the 7MM
7.4 Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in the 7MM
7.5 The United States
7.5.1 Total Prevalent Cases of 22q11.2 Deletion Syndrome in the United States
7.5.2 Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in the United States
7.5.3 Age-specific Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in the United States
7.5.4 Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric in the United States
7.5.5 Total Treated Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in the United States
7.6 EU4 and the UK
7.6.1 Total Prevalent Cases of 22q11.2 Deletion Syndrome in EU4 and the UK
7.6.2 Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in EU4 and the UK
7.6.3 Age-specific Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in EU4 and the UK
7.6.4 Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric in EU4 and the UK
7.6.5 Total Treated Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in EU4 and the UK
7.7 Japan
7.7.1 Total Prevalent Cases of 22q11.2 Deletion Syndrome in Japan
7.7.2 Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in Japan
7.7.3 Age-specific Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in Japan
7.7.4 Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric in Japan
7.7.5 Total Treated Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in Japan
8. Appendix
8.1 Bibliography
8.2 Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
List of Tables:
List of Tables
Table 1: Summary of 22q11.2 Deletion Syndrome Epidemiology and Market
Table 2: Common Signs and Symptoms Observed in Patients With 22q11.2 Deletion Syndrome
Table 3: Recommended Surveillance for Individuals with 22q11.2 Deletion Syndrome
Table 4: Genetic Counseling Strategies for Adults With 22q11.2 Deletion Syndrome With Intellectual Disabilities and/or Psychotic Illness
Table 5: Recommendations for Investigation and Referral
Table 6: Total Prevalent Cases of 22q11.2 Deletion Syndrome in 7MM (2022–2036)
Table 7: Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in 7MM (2022–2036)
Table 8: Total Prevalent Cases of 22q11.2 Deletion Syndrome in the United States (2022–2036)
Table 9: Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in the United States (2022–2036)
Table 10: Total Treated Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in the United States (2022–2036)
Table 11: Age-specific Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in the United States (2022–2036)
Table 12: Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in the United States (2022–2036)
Table 13: Total Treated Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in the United States (2022–2036)
Table 14: Total Prevalent Cases of 22q11.2 Deletion Syndrome in EU4 and the UK (2022–2036)
Table 15: Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in EU4 and the UK (2022–2036)
Table 16: Total Treated Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in EU4 and the UK (2022–2036)
Table 17: Age-specific Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in EU4 and the UK (2022–2036)
Table 18: Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in EU4 and the UK (2022–2036)
Table 19: Total Treated Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in EU4 and the UK (2022–2036)
Table 20: Total Prevalent Cases of 22q11.2 Deletion Syndrome in Japan (2022–2036)
Table 21: Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in Japan (2022–2036)
Table 22: Total Treated Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in Japan (2022–2036)
Table 23: Age-specific Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in Japan (2022–2036)
Table 24: Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in Japan (2022–2036)
Table 25: Total Treated Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in Japan (2022–2036)
List of Figures:
List of Figures
Figure 1: Diagnostic Algorithm
Figure 2: Total Prevalent Cases of 22q11.2 Deletion Syndrome in 7MM (2022–2036)
Figure 3: Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in 7MM (2022–2036)
Figure 4: Total Prevalent Cases of 22q11.2 Deletion Syndrome in the United States (2022–2036)
Figure 5: Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in the United States (2022–2036)
Figure 6: Total Treated Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in the United States (2022–2036)
Figure 7: Age-specific Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in the United States (2022–2036)
Figure 8: Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in the United States (2022–2036)
Figure 9: Total Treated Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in the United States (2022–2036)
Figure 10: Total Prevalent Cases of 22q11.2 Deletion Syndrome in EU4 and the UK (2022–2036)
Figure 11: Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in EU4 and the UK (2022–2036)
Figure 12: Total Treated Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in EU4 and the UK (2022–2036)
Figure 13: Age-specific Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in EU4 and the UK (2022–2036)
Figure 14: Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in EU4 and the UK (2022–2036)
Figure 15: Total Treated Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in EU4 and the UK (2022–2036)
Figure 16: Total Prevalent Cases of 22q11.2 Deletion Syndrome in Japan (2022–2036)
Figure 17: Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in Japan (2022–2036)
Figure 18: Total Treated Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in Japan (2022–2036)
Figure 19: Age-specific Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome in Japan (2022–2036)
Figure 20: Total Diagnosed Prevalent Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in Japan (2022–2036)
Figure 21: Total Treated Cases of 22q11.2 Deletion Syndrome with Behavioral and Psychiatric Phenotypes in Japan (2022–2036)
*The table of contents is not exhaustive; will be provided in the final report
